GGrantIndex
← Leaderboards

Claus Schneider

Vanderbilt University

$9,629,126
Attributed
$9,629,126
Total exposure
5
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $824.6K · FY200725
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$9,629,126 · 5

By mechanism

R01$7,577,424 · 3
R35$1,900,382 · 1
R03$151,320 · 1

Top collaborators

No co-investigators on record.

Most similar at Vanderbilt University

Same institution · by research overlap

Others in their field

Top investigators on “Inflammatory

Research focus

InflammatoryProstaglandinsInflammationEicosanoidsPharmaceutical PreparationsAnabolismPathway InteractionsIn VitroLeukotrienesBaseTissuesEnzymesMetabolismAnti-InflammatoryIn VivoArachidonic AcidsAspirinLipoxygenaseProstaglandin D2Prostaglandin-Endoperoxide SynthaseMediator Of Activation ProteinBiologicalAnti-Inflammatory AgentsMalignant Neoplasms

Grant awards (31)

Novel pathways in eicosanoid biosynthesis and metabolism$473,882
R35 · FY2025 · GM · contact PI
Novel pathways in eicosanoid biosynthesis and metabolism$475,500
R35 · FY2024 · GM · contact PI
Novel pathways in eicosanoid biosynthesis and metabolism$475,500
R35 · FY2023 · GM · contact PI
Novel pathways in eicosanoid biosynthesis and metabolism$475,500
R35 · FY2022 · GM · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$312,510
R01 · FY2021 · GM · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$312,510
R01 · FY2020 · GM · contact PI
Novel Pathways of Eicosanoid Metabolism$310,432
R01 · FY2020 · GM · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$312,510
R01 · FY2019 · GM · contact PI
Novel Pathways of Eicosanoid Metabolism$310,425
R01 · FY2019 · GM · contact PI
Novel Pathways of Eicosanoid Metabolism$54,727
R01 · FY2019 · GM · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$54,727
R01 · FY2019 · GM · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$326,760
R01 · FY2018 · GM · contact PI
Novel Pathways of Eicosanoid Metabolism$310,419
R01 · FY2018 · GM · contact PI
Oxidative activation of the dietary cancer chemopreventive agent curcumin$409,921
R01 · FY2017 · AT · contact PI
Novel Pathways of Eicosanoid Metabolism$321,669
R01 · FY2017 · GM · contact PI
Oxidative activation of the dietary cancer chemopreventive agent curcumin$522,897
R01 · FY2016 · AT · contact PI
Oxidative activation of the dietary cancer chemopreventive agent curcumin$420,429
R01 · FY2015 · AT · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$313,560
R01 · FY2015 · GM · contact PI
Oxidative activation of the dietary cancer chemopreventive agent curcumin$431,798
R01 · FY2014 · AT · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$313,560
R01 · FY2014 · GM · contact PI
Oxidative activation of the dietary cancer chemopreventive agent curcumin$448,716
R01 · FY2013 · AT · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$302,585
R01 · FY2013 · GM · contact PI
Pharmacokinetics and Metabolism of Oxidized Curcumin$73,320
R03 · FY2013 · CA · contact PI
Convergence of the Cox-2 and 5-Lipoxygenase Pathways$313,560
R01 · FY2012 · GM · contact PI
Pharmacokinetics and Metabolism of Oxidized Curcumin$78,000
R03 · FY2012 · CA · contact PI
Convergence of the COX-2 and 5-lipoxygenase pathways$285,847
R01 · FY2011 · GM · contact PI
Convergence of the COX-2 and 5-lipoxygenase pathways$288,734
R01 · FY2010 · GM · contact PI
Convergence of the COX-2 and 5-lipoxygenase pathways$291,650
R01 · FY2009 · GM · contact PI
Convergence of the COX-2 and 5-lipoxygenase pathways$55,053
R01 · FY2009 · GM · contact PI
Convergence of the COX-2 and 5-lipoxygenase pathways$281,485
R01 · FY2008 · GM · contact PI
Convergence of the COX-2 and 5-lipoxygenase pathways$270,940
R01 · FY2007 · GM · contact PI